Alvotech tekur þátt í árlegri heilbrigðisráðstefnu fjárfestingabankans Morgans Stanley
26 août 2024 09h15 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tekur þátt í 22. árlegri heilbrigðisráðstefnu fjárfestingabankans Morgans Stanleys í New York. Fulltrúar framkvæmdastjórnar félagsins munu meðal annars sitja fyrir svörum...
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
26 août 2024 09h15 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd...
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
26 août 2024 09h14 HE
|
Alvotech
REYKJAVIK, Iceland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech skilar mettekjum og metframlegð á öðrum ársfjórðungi og á fyrri helmingi ársins
15 août 2024 16h15 HE
|
Alvotech
Heildartekjur voru 236 milljónir dollara á fyrri helmingi ársins, sem er meira en tíföldun frá sama tímabili í fyrraTekjur af vörusölu á fyrri helmingi ársins jukust um 190% frá sama tímabili í fyrra...
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
15 août 2024 16h15 HE
|
Alvotech
Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023Product revenues for the first six months were $66 million, a 190%...
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
15 août 2024 16h15 HE
|
Alvotech
Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023 Product revenues for the first six months were $66...
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
15 août 2024 04h30 HE
|
Alvotech
The approvals process is anticipated to be completed in the third quarter of 2025 REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company...
Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT06, fyrirhugaða líftæknilyfjahliðstæðu við Eylea
15 août 2024 04h30 HE
|
Alvotech
Markaðsleyfi fyrir Evrópu gæti verið veitt á þriðja fjórðungi næsta árs Alvotech (NASDAQ: ALVO) og samstarfsaðili þess, alþjóðlega lyfjafyrirtækið Advanz Pharma tilkynntu í dag að Lyfjastofnun...
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
15 août 2024 04h30 HE
|
Alvotech
The approvals process is anticipated to be completed in the third quarter of 2025 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
01 août 2024 16h02 HE
|
Alvotech
REYKJAVIK, Iceland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...